{"id":107756,"title":"Avacta Group PLC has announced that the first patient has been dosed in the US in the AVA6000 Phase 1 trial.","publisher":"Share Talk","author":"sharetalk","published":"2023-04-27T09:00:56+00:00","modified":"2023-04-27T09:00:56+00:00","canonical_url":"https://www.share-talk.com/avacta-group-plc-has-announced-that-the-first-patient-has-been-dosed-in-the-us-in-the-ava6000-phase-1-trial/","markdown_url":"https://www.share-talk.com/avacta-group-plc-has-announced-that-the-first-patient-has-been-dosed-in-the-us-in-the-ava6000-phase-1-trial.md","json_url":"https://www.share-talk.com/avacta-group-plc-has-announced-that-the-first-patient-has-been-dosed-in-the-us-in-the-ava6000-phase-1-trial.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Abingdon Health","AffyXell Therapeutics","antigen","Avacta Group","AVCT","Biotherapeutics","Chris Yates","clinical","COVID-19","Cytiva","Daewoong Pharmaceutical","diagnostic","Doncaster","Europe","LG Chem Life Sciences","Pharma","radiopharmaceuticals","saliva test","SARS-COV-2","Sengho Jeon","Share Talk","South Korea","therapeutic","UK","validation","York"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**Avacta Group plc**, a life sciences company that develops targeted oncology drugs and diagnostics, has dosed the first patient in the US as part of its phase 1 multi-center trial to evaluate the safety and tolerability of AVA6000.\n\nThis is a novel, tumour-targeted form of doxorubicin and Avacta’s first therapeutic product that is based on the company’s proprietary pre|CISION™ technology, under its Investigational New Drug (IND) Application.\n\nThe dose-escalation study for locally advanced or metastatic selected solid tumors, which are known to be FAP-positive, will take place at the Memorial Sloan Kettering Cancer Center in New York. More information on the trial can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov/) (NCT04969835).\n\nDr Alastair Smith, CEO of Avacta Group plc, noted that New York and Seattle US trial sites, along with other locations in the UK and US, would play a crucial role in both the dose escalation and dose expansion phases of the multi-center trial, which is expected to start in the second half of the year.\n\nDosing the first patient in the US is a significant milestone and reflects the ongoing progress in the ALS-6000-101 clinical trial and the Therapeutics Division as a whole, he added."}